[EN] TRICYCLIC IMIDAZOPYRIDINES FOR USE AS GASTRIC SECRETION INHIBITORS [FR] IMIDAZOPYRIDINES TRICYCLIQUES UTILISEES COMME INHIBITEURS DE SECRETION GASTRIQUE
The invention provides compounds of the formula (I), in which the substituents and symbols are as defined in the description. The compounds inhibit the secretion of gastric acid.
该发明提供了公式(I)的化合物,其中置换基和符号如描述中所定义。这些化合物抑制胃酸分泌。
Tricyclic imidzopyridines for use as gastric secretion inhibitors
申请人:Palmer Andreas
公开号:US20070066674A1
公开(公告)日:2007-03-22
The invention provides compounds of the formula 1,
in which the substituents and symbols are as defined in the description. The compounds inhibit the secretion of gastric acid.
该发明提供了式1的化合物,其中取代基和符号如描述中所定义。这些化合物可抑制胃酸分泌。
Preparation of tricyclic imidazopyridines by asymmetric ketone hydrogenation in the presence of RuCl2[(S)-Xyl-P-Phos][(S)-DAIPEN]
作者:Andreas Marc Palmer、Antonio Zanotti-Gerosa、Hans Nedden
DOI:10.1016/j.tetasy.2008.05.013
日期:2008.6
The novel complex RuCl2[(S)-Xyl-P-Phos][(S)-DAIPEN] was identified as a highly active catalyst for the asymmetric reduction of a variety of prochiral ketones possessing an imidazo[1,2-a]pyridine scaffold. The corresponding alcohols were obtained in excellent enantiomeric purities (>96% ee) and served as valuable intermediates for the synthesis of pharmacologically active 7H-8,9-dihydropyrano[2,3-c]imidazo[ 1,2-alpyridines. The complexity of these multi-functional substrates required the development of specific reaction conditions. Whereas the reduction with RuCl2[PP][NN] catalysts (Noyori catalysts) has never been reported to occur under aqueous conditions, in the present case, the use of aqueous isopropanol or tert-butanol was not only tolerated, but also turned out to be beneficial, especially when the reduction was conducted at high substrate to catalyst (S/C) ratios. (C) 2008 Elsevier Ltd. All rights reserved.